| Not Yet Recruiting | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease NCT07420439 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Not Yet Recruiting | Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tum NCT07462728 | Guizhou Medical University | N/A |
| Recruiting | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477 | University of California, Davis | Phase 2 |
| Recruiting | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic NCT07292168 | Kidney Cancer Research Bureau | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants NCT07144280 | Pfizer | Phase 3 |
| Recruiting | PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573 | Fundación GECP | Phase 2 |
| Not Yet Recruiting | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non- NCT06848426 | Jiangxi Provincial People's Hopital | N/A |
| Recruiting | First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NIC NCT07190677 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread t NCT06741085 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung C NCT07111104 | Hopitaux Prives de Metz, Groupe UNEOS | — |
| Recruiting | A Phase Ib Study of GC101 in NSCLC NCT06473961 | Shanghai Juncell Therapeutics | Phase 1 |
| Recruiting | Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations NCT06517953 | Sun Yat-sen University | Phase 2 |
| Recruiting | Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib NCT06106802 | Samsung Medical Center | Phase 2 |
| Not Yet Recruiting | T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer NCT06045767 | Ari Raphael | Phase 2 |
| Recruiting | Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer NCT05864794 | University Medical Center Groningen | N/A |
| Withdrawn | JDQ443 for KRAS G12C NSCLC Brain Metastases NCT05999357 | Maastricht University Medical Center | Phase 2 |
| Recruiting | A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive NCT06378892 | Centro di Riferimento Oncologico - Aviano | Phase 2 |
| Completed | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGF NCT06812871 | Sun Yat-sen University | Phase 2 |
| Recruiting | An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC NCT06083870 | Lu Shun | Phase 1 |
| Active Not Recruiting | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma NCT05689671 | Nikolaj Frost MD | Phase 4 |
| Unknown | K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation NCT06127940 | Karolinska University Hospital | Phase 1 |
| Unknown | Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI NCT06100796 | Assiut University | — |
| Recruiting | Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage I NCT05668650 | Laboratorio Elea Phoenix S.A. | Phase 3 |
| Recruiting | Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer NCT05889247 | Zealand University Hospital | N/A |
| Active Not Recruiting | Liquid Biopsy Based NGS in Newly Diagnosed NSCLC NCT05853887 | Charu Aggarwal | N/A |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Unknown | Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) NCT05599789 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer NCT05800223 | Shanghai Cancer Hospital, China | Phase 3 |
| Recruiting | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) NCT05429320 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC NCT05265650 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 1 / Phase 2 |
| Unknown | Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer NCT05407155 | Fudan University | N/A |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Unknown | Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomati NCT05638425 | Xiangya Hospital of Central South University | — |
| Unknown | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell NCT05472467 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Active Not Recruiting | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma NCT04951583 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Active Not Recruiting | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of R NCT05117242 | Genmab | Phase 2 |
| Active Not Recruiting | Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV NCT04994795 | Sophia Genetics SAS | — |
| Completed | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients NCT04923945 | Hutchison Medipharma Limited | Phase 3 |
| Active Not Recruiting | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cance NCT04563338 | University Health Network, Toronto | Phase 2 |
| Completed | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) NCT04793815 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Active Not Recruiting | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and NCT04868877 | Merus B.V. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat NCT04836728 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Active Not Recruiting | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) NCT04621188 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Active Not Recruiting | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small NCT04619004 | Daiichi Sankyo | Phase 2 |
| Active Not Recruiting | Dacomitinib in Lung Cancer With Uncommon EGFR Mutations NCT04504071 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Almonertinib With Chemotherapy in mEGFR NSCLC NCT04646824 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors NCT04471415 | Dracen Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretrea NCT04394624 | Sanofi | Phase 2 |
| Completed | Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. NCT04749602 | Kidney Cancer Research Bureau | Phase 2 |
| Completed | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-po NCT04111705 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chi NCT05110118 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Completed | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation NCT04233021 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Active Not Recruiting | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squa NCT04163432 | University of Utah | Phase 2 |
| Unknown | Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC NCT04331626 | Henan Cancer Hospital | Phase 4 |
| Active Not Recruiting | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (C NCT04154956 | Sanofi | Phase 3 |
| Completed | Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer NCT04187768 | Indiana University | — |
| Completed | Thyroid Dysfunction and Nivolumab Reponse in NSCLC NCT04470440 | University Hospital, Brest | — |
| Terminated | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivo NCT04069936 | WindMIL Therapeutics | Phase 2 |
| Unknown | Evolution of the Physical Condition in Treated Cancer Patients NCT03956641 | Centre Paul Strauss | N/A |
| Unknown | MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer NCT04082182 | University Hospital, Ghent | Phase 1 |
| Active Not Recruiting | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel NCT03977194 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Completed | Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Th NCT04009122 | Igen BioLab SLU | N/A |
| Completed | Her2-positive Lung Cancer Treated With Dedicated Drug NCT03845270 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Active Not Recruiting | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer NCT03846310 | Arcus Biosciences, Inc. | Phase 1 |
| Unknown | Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Sma NCT03732482 | Taizhou Hospital | Phase 2 / Phase 3 |
| Completed | Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC NCT03732274 | MedPacto, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC NCT03611738 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib NCT03727477 | Intergroupe Francophone de Cancerologie Thoracique | — |
| Unknown | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) NCT03715985 | Herlev Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Ca NCT03808662 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC NCT03916913 | Chinese Academy of Medical Sciences | N/A |
| Terminated | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer NCT03445000 | ETOP IBCSG Partners Foundation | Phase 2 |
| Unknown | Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors NCT03656094 | Samsung Medical Center | Phase 2 |
| Completed | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr NCT03469960 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Terminated | Registry of Guardant360® Use and Outcomes In People With Advanced Cancer NCT03477474 | Guardant Health, Inc. | — |
| Active Not Recruiting | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer NCT03377023 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell NCT03774732 | UNICANCER | Phase 3 |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Completed | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccin NCT03353675 | Transgene | Phase 2 |
| Unknown | A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors NCT03424980 | Tang-Du Hospital | — |
| Active Not Recruiting | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b NCT03319628 | Mersana Therapeutics | Phase 1 / Phase 2 |
| Completed | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b NCT06517433 | Mersana Therapeutics | Phase 1 |
| Terminated | Survival Prolongation by Rationale Innovative Genomics NCT03386929 | Worldwide Innovative Network Association | Phase 1 / Phase 2 |
| Unknown | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects Wi NCT03533127 | Luye Pharma Group Ltd. | Phase 3 |
| Unknown | Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis NCT03363685 | Ruijin Hospital | — |
| Completed | Immunotherapy by Nivolumab for HIV+ Patients NCT03304093 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 NCT03307785 | Tesaro, Inc. | Phase 1 |
| Terminated | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) NCT03168464 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Unknown | Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable NCT03240549 | Beijing Hospital | Phase 2 |
| Completed | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab NCT03123783 | Apexigen America, Inc. | Phase 1 / Phase 2 |
| Completed | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases NCT02978404 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Completed | Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Con NCT03133546 | ETOP IBCSG Partners Foundation | Phase 2 |
| Unknown | Cancer Panel From Blood of Lung Cancer Patients NCT03235765 | Seoul National University Hospital | — |
| Completed | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK NCT02959619 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer NCT03035890 | West Virginia University | N/A |
| Completed | High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer NCT03007875 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Unknown | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer NCT06207292 | Radiotherapy Oncology Centre "Santa Maria" Hospital | N/A |
| Terminated | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer NCT02967133 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer NCT02922764 | Inspirna, Inc. | Phase 1 |
| Unknown | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC NCT02946216 | First People's Hospital of Hangzhou | — |
| Completed | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT02812667 | Lyudmila Bazhenova, M.D. | Phase 1 |
| Completed | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer NCT02843815 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Completed | EGFR Mutations on ctDNA in Patients With Advanced NSCLC NCT02623257 | First People's Hospital of Hangzhou | — |
| Recruiting | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Pa NCT02622581 | AIO-Studien-gGmbH | — |
| Terminated | A Study of LY3023414 and Necitumumab in Squamous Lung Cancer NCT02443337 | Eli Lilly and Company | Phase 2 |
| Completed | T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure NCT02418234 | First People's Hospital of Hangzhou | — |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Terminated | Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients NCT02228421 | PeriPharm | — |
| Completed | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC NCT02314364 | Massachusetts General Hospital | Phase 2 |
| Terminated | Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC NCT02299765 | Sichuan University | Phase 4 |
| Completed | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients NCT02117167 | UNICANCER | Phase 2 |
| Unknown | Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients NCT03334071 | University Hospital Southampton NHS Foundation Trust | N/A |
| Unknown | Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients NCT02041468 | Jewish General Hospital | — |
| Terminated | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases NCT02162537 | Centre Hospitalier Intercommunal Creteil | Phase 3 |
| Completed | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous No NCT01999673 | Peregrine Pharmaceuticals | Phase 3 |
| Terminated | Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Smal NCT02019979 | Beth Israel Medical Center | Phase 2 |
| Completed | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung C NCT01966003 | Amgen | Phase 3 |
| Unknown | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy NCT02035683 | National Cancer Institute, Naples | N/A |
| Terminated | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced N NCT01798485 | Synta Pharmaceuticals Corp. | Phase 3 |
| Terminated | A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. NCT01752023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell NCT01703091 | Eli Lilly and Company | Phase 2 |
| Completed | Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung NCT01705184 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC NCT01848613 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 4 |
| Unknown | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous L NCT01656551 | National Cancer Institute, Naples | Phase 3 |
| Completed | Efficacy Study of Vx001 Vaccine in NSCLC Patients NCT01935154 | Vaxon Biotech | Phase 2 |
| Completed | 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lu NCT01658813 | Western Regional Medical Center | Phase 2 |
| Completed | A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell NCT01473563 | Eli Lilly and Company | Phase 2 |
| Terminated | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung NCT01471964 | Fox Chase Cancer Center | Phase 1 / Phase 2 |
| Completed | A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotini NCT01523340 | Chonnam National University Hospital | — |
| Terminated | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer NCT01348126 | Synta Pharmaceuticals Corp. | Phase 2 / Phase 3 |
| Terminated | Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial C NCT01380795 | Centre Georges Francois Leclerc | EARLY_Phase 1 |
| Unknown | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer NCT01405586 | National Cancer Institute, Naples | Phase 3 |
| Terminated | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network NCT01574300 | Addario Lung Cancer Medical Institute | — |
| Suspended | Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer NCT01320501 | National Guard Health Affairs | Phase 4 |
| Suspended | Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer NCT01356303 | National Guard Health Affairs | Phase 2 |
| Completed | A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unre NCT00701558 | Hoffmann-La Roche | Phase 2 |